Paraguay's approach to biotechnology governance: a comprehensive guide.

This study analyzes Paraguay's biotechnology regulatory framework and its alignment with international standards amid biotechnological advancements. It also identifies areas of improvement for enhancing framework effectiveness. Through this work, we aim to provide a resource for policymakers, stakeholders, and researchers navigating Paraguay's biotechnology regulation.

Vacunas contra el virus chikungunya: avances y perspectivas

El virus chikungunya (CHIKV) es un alfavirus cuya infección provoca una enfermedad caracterizada principalmente por fiebre y dolores articulares/musculares. Entre 25-50% de las infecciones se presentan con enfermedad crónica que puede durar de meses a años. El primer brote de CHIKV en Paraguay corresponde al año 2015, siendo el último en el año 2022/2023. Diversos candidatos vacunales contra CHIKV se encuentran en diferentes etapas de desarrollo, e incluso recientemente (noviembre/2023) fue aprobada la primera vacuna contra CHIKV llamada VLA1553 (Ixchiq). Adicionalmente, al menos 30 candidatos vacunales se encuentran en ensayos preclínicos/clínicos. Con la aprobación de la primera vacuna contra CHIKV y la posibilidad de otras que lleguen al mercado prontamente, debido al estado avanzado de otros candidatos vacunales, se abrirá un nuevo escenario en esta enfermedad. Se espera que la introducción de vacunas efectivas genere un avance importante para la prevención de esta enfermedad, disminuyendo los casos agudos y los efectos crónicos de la infección por el virus. En este trabajo de revisión se analiza el avance de las vacunas contra CHIKV, además de examinar los desafíos de vigilancia epidemiológica que plantean la introducción de estas vacunas.

Chikungunya virus (CHIKV) is an alphavirus that causes an illness characterized mainly by fever and joint/muscle pain. Between 25-50% of infections present with chronic diseases that can last from months to years. The first outbreak of CHIKV in Paraguay occurred in 2015, with the last outbreak occurring in 2022/2023. Several vaccine candidates against CHIKV are in different stages of development, and even recently (November/2023), the first vaccine against CHIKV, called VLA1553 (Ixchiq), was approved. In addition, at least 30 vaccine candidates are available for preclinical and clinical trials. With the approval of the first vaccine against CHIKV and the possibility of others coming to the market soon, due to the advanced status of other vaccine candidates, a new scenario will open for this disease. The introduction of effective vaccines is expected to generate an important advance in the prevention of this disease, reducing acute cases and the chronic effects of viral infection. This review analyzes the progress of CHIKV vaccines and examines the epidemiological surveillance challenges posed by the introduction of these vaccines.

Neutralizing antibodies from naturally infected individuals against SARS-CoV-2 Gamma and Delta variants in the Paraguayan population.

INTRODUCTION: Severe Acute Respiratory Syndrome-Coronavirus-2 Virus (SARS-CoV-2) is responsible for Coronavirus Disease 2019 (COVID-19). A substantial number of SARS-CoV-2 infection cases have been reported during the pandemic, and vaccination coverage in some regions, particularly in developing countries, remains very low. SARS-CoV-2 variants of concern (VOCs) have also emerged as some of the most pressing public health issues. In this scenario, it is crucial to know whether COVID-19 convalescent antibodies have cross-neutralizing action against VOCs to contribute to the analysis of the future progress of the pandemic. METHODOLOGY: The plasma of individuals infected with SARS-CoV-2 from June to November 2020 in Paraguay (before the first recorded infections associated with VOCs in the country) was selected. Anti-spike antibodies were determined in plasma samples (n = 626) obtained from this convalescent and unvaccinated group. Using a pseudotyped virus neutralization assay, we then investigated the neutralizing response against D614G variant and Gamma, and Delta VOCs. RESULTS: IgG antibodies against spike were detected in 85.6% of convalescent individuals. Samples from individuals previously infected by a non-VOC showed a 6.6- and 8.1-fold reduction in neutralizing capacity to the Gamma and Delta variants, respectively, when compared to the D614G variant. CONCLUSIONS: Our findings show that antibodies generated by non-VOC infection have reduced neutralizing capabilities against Gamma and Delta variants that appeared subsequently and might have implications for immunity strategies.

Inhibitory Activity of Saussurea costus Extract against Bacteria, Candida, Herpes, and SARS-CoV-2.

Medicinal herbs have long been utilized to treat various diseases or to relieve the symptoms of some ailments for extended periods. The present investigation demonstrates the phytochemical profile, molecular docking, anti-Candida activity, and anti-viral activity of the Saussurea costus acetic acid extract. GC-MS analysis of the extract revealed the presence of 69 chemical compounds. The chemical compounds were alkaloids (4%), terpenoids (79%), phenolic compounds (4%), hydrocarbons (7%), and sterols (6%). Molecular docking was used to study the inhibitory activity of 69 identified compounds against SARS-CoV-2. In total, 12 out of 69 compounds were found to have active properties exhibiting SARS-CoV-2 inhibition. The binding scores of these molecules were significantly low, ranging from -7.8 to -5.6 kcal/mol. The interaction of oxatricyclo [20.8.0.0(7,16)] triaconta-1(22),7(16),9,13,23,29-hexaene with the active site is more efficient. Furthermore, the extract exhibited significant antimicrobial activity (in vitro) against Candida albicans, which was the most susceptible microorganism, followed by Bacillus cereus, Salmonella enterica, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, respectively. On the other hand, its antiviral activity was evaluated against HSV-1 and SARS-CoV-2, and the results showed a significant positive influence against HSV-1 (EC50 = 82.6 g/mL; CC50 = 162.9 g/mL; selectivity index = 1.9). In spite of this, no impact could be observed in terms of inhibiting the entry of SARS-CoV-2 in vitro.

Antiviral activity of two Acanthospermum species against herpes simplex virus 1.

ETHNOPHARMACOLOGICAL RELEVANCE: Acanthospermum species are used in traditional medicine for treating various pathologies, including bacterial and viral infections. In a screening study, we identified the activity of the ethanolic extracts of Acanthospermum australe and Acanthospermum hispidum against herpes simplex virus 1 (HSV-1). AIM OF THE STUDY: In this work, we analyzed the phytochemical profile and antiviral activity of the chemical fractionation products of Acanthospermum australe and Acanthospermum hispidum. Additionally, we identified the effect of these fractions on different steps of the viral cycle. MATERIALS AND METHODS: Acanthospermum samples were extracted with methanol and further partitioned with solvents of increasing polarities: hexane, chloroform, ethyl acetate, and butanol. Cytotoxicity and antiviral activity were analyzed for each fraction. The active fractions were tested to identify the virucidal effect and the inhibition of virus-cell binding. Further, the effect of these fractions on the replication and viral gene was quantitated by qPCR, and the expression of gD protein was evaluated by Western blot. RESULTS: The chloroform and hexane fractions of Acanthospermum hispidum and Acanthospermum australe showed dose-dependent antiviral activity. The chloroform fraction inhibited the virus-cell binding and virus cycle in a post-entry mechanism by decreasing replication and the expression of early and late viral genes. The hexane fraction did not inhibit virus binding; however, it showed antiviral activity in post-entry events by inhibiting the immediate-early, early, and late genes. We identified in both species the presence of 3.6-dimetoxiapigenin, axillarin, and penduletin in the chloroform fraction and methyl-(Z,Z)-9,12-octadecadienoate and phytol in the hexane fraction. CONCLUSIONS: Acanthospermum hispidum and Acanthospermum australe possess antiviral activity against HSV-1 and affect different steps of the viral cycle. These characteristics make them good candidates for developing phytotherapeutic products against HSV-1.

Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.

The COVID-19 pandemic has led to the search for new molecules with antiviral activity against SARS-CoV-2. The entry of the virus into the cell is one of the main targets for inhibiting SARS-CoV-2 infection. Natural products are an important source of new therapeutic alternatives against diseases. Pseudotyped viruses allow the study of SARS-CoV-2 viral entry inhibitors, and due to their simplicity, they allow the screening of a large number of antiviral candidates in Biosafety Level 2 facilities. We used pseudotyped HIV-1 with the D614G SARS-CoV-2 spike glycoprotein to test its ability to infect ACE2-expressing HEK 293T cells in the presence of diverse natural products, including 21 plant extracts, 7 essential oils, and 13 compounds from plants and fungi. The 50% cytotoxic concentration (CC50) was evaluated using the resazurin method. From these analyses, we determined the inhibitory activity of the extract of Stachytarpheta cayennensis, which had a half-maximal inhibitory concentration (IC50) of 91.65 µg/mL, a CC50 of 693.5 µg/mL, and a selectivity index (SI) of 7.57, indicating its potential use as an inhibitor of SARS-CoV-2 entry. Moreover, our work indicates the usefulness of the pseudotyped-virus system in the screening of SARS-CoV-2 entry inhibitors.

Development of a new promoter to avoid the silencing of genes in the production of recombinant antibodies in chinese hamster ovary cells.

BACKGROUND: The production of recombinant proteins in mammalian cell lines is one of the most important areas in biopharmaceutical industry. Viral transcriptional promoters are widely used to express recombinant proteins in mammalian cell lines. However, these promoters are susceptible to silencing, thus limiting protein productivity. Some CpG islands can avoid the silencing of housekeeping genes; for that reason, they have been used to increase the production of recombinant genes in cells of animal origin. In this study, we evaluated the CpG island of the promoter region of the ß-actin gene of Cricetulus griseous (Chinese hamster), associated to the Cytomegalovirus (CMV) promoter, to increase recombinant antibodies production in Chinese Hamster Ovary (CHO) cells. RESULTS: We focused on the non-coding region of CpG island, which we called RegCG. RegCG behaved as a promoter, whose transcriptional activity was mainly commanded by the CAAT and CArG boxes of the proximal promoter. However, the transcription started mainly at the intronic region before the proximal transcription start site. While the CMV promoter was initially more powerful than RegCG, the latter promoter was more resistant to silencing than the CMV promoter in stable cell lines, and its activity was improved when combined with the CMV promoter. Thereby, the chimeric promoter was able to maintain the expression of recombinant antibodies in stable clones for 40 days at an average level 4 times higher than the CMV promoter. Finally, the chimeric promoter showed compatibility with a genetic amplification system by induction with methotrexate in cells deficient in the dihydrofolate reductase gene. CONCLUSIONS: We have generated an efficient synthetic hybrid transcription promoter through the combination of RegCG with CMV, which, in stable cell lines, shows greater activity than when both promoters are used separately. Our chimeric promoter is compatible with a genetic amplification system in CHO DG44 cells and makes possible the generation of stable cell lines with high production of recombinant antibodies. We propose that this promoter can be a good alternative for the generation of clones expressing high amount of recombinant proteins, essential for industrial applications.

Estabilidade dimensional de moldes obtidos com alginato de armazenamento tardio / Dimensional stability of molds obtained with late storage alginate

Resumo Introdução Recentemente, vêm surgindo no mercado alguns alginatos de armazenamento prolongado. Não há, no entanto, um consenso na literatura a respeito da estabilidade dimensional destes materiais durante este armazenamento Objetivo Avaliar, por meio de método prático experimental, a estabilidade dimensional de um alginato de armazenamento tardio. Material e método O material de moldagem utilizado foi o alginato Hydrogum 5 (Zhermack). Uma matriz metálica cilíndrica foi utilizada para a realização das moldagens, com 38 mm de diâmetro externo, 30 mm de diâmetro interno e cuja superfície superior apresenta três linhas paralelas entre si com 25 mm de comprimento e 20, 50 e 75 µm de largura. Após o tempo de geleificação do material de moldagem, 16 moldes foram colocados em um umidificador e essas amostras foram fotografadas utilizando-se uma câmera digital (Canon EOS Rebel 3Ti, Canon) associada a um software para análise das imagens obtidas (ImageJ 1.52a, U.S. National Institutes of Health; DI). A calibragem da régua foi 10 cm e, posteriormente, três linhas foram medidas três vezes, para se obter uma média dos comprimentos das linhas. As amostras foram fotografadas nos seguintes intervalos: imediatamente, 24, 48, 72, 96 e 120 horas. Resultado Os dados mostraram diferenças estatisticamente significantes para o fator tempo quando comparada a leitura imediata com os demais períodos de tempo de leitura (p<0,001) e quando comparada a leitura após 24 h de armazenagem com os demais períodos de tempo (p<0,001). Não houve diferença estatística (p>0,05) quando os tempos de armazenamento de 48 h, 72 h, 96 h e 120 h foram comparados entre si. Todos os valores encontravam-se dentro dos valores preconizados pela ISO 21563:2013. Conclusão Os moldes dos alginatos testados podem ser armazenados por até cinco dias em 100% de umidade relativa.

Abstract Introduction Recently, some extended-pour alginate impression materials have been placed in the market. However, there is no consensus in the literature regarding the dimensional stability of these materials during these storage. Objective To evaluate, through the experimental model, the durability and velocity with respect to dimensional alteration, analyzing the material and detecting distortions. Material and method The material for molding in this test was alginate (Hydrogum 5, Zhermack). A cylindrical metallic matrix was used to make the moldings with: 38 mm of external diameter, 30 mm of internal diameter and superior of the upper series of the card 3d transport lines with each 25 mm in length and 20, 50 and 75μm in width. After the time of jellification / polymerization of the molding material, 16 molds were inserted in a doser and were photographed with a digital camera (Canon EOS Rebel 3Ti, Canon) associated with a software for analysis of sacred images (ImageJ 1.52a, US National Institutes of Health, DI). The calibration of the ruler was performed in 10 cm and then in 3 lines were means 3 (three) times to obtain a mean of the lengths of the lines. The photographs were taken at the following intervals: immediately, 24, 48, 72, 96 and 120 hours after being cast. Result The data were found when compared with the other parts of the reading time (p <0.001) and when compared to the execution after 24 hours of locomotion with the other parts of the time (p <0.001). The rest time of 48 hours, 72 hours, 96 hours and 120 hours were compared to each other. Conclusion The molds of the tested alginates can be stored for 5 days in 100% relative sauce.

Extractos vegetales de tres especies del género Baccharis inducen la proliferación de células mononucleares humanas / Plant extracts of three species of the genus Baccharis induce human mononuclear cells proliferation

Las plantas de uso en medicina tradicional constituyen una fuente importante de compuestos con actividad inmunomoduladora; entre ellas las especies del género Baccharis, conocidas popularmente como "Jaguareteka´a" en nuestro país, son ampliamente empleadas. En este estudio se evaluó la actividad inmunomoduladora de extractos metanólicos de tres especies del género Baccharis (B. trimera, B. notosergilay B. punctulata) sobre la proliferación de células mononucleares humanas de sangre periférica. Los extractos de las tres especies estudiadas estimularon la proliferación de las células mononucleares. Específicamente, el extracto de B. notosergila estimuló la proliferación celular a todas las concentraciones probadas (5, 10, 25 y 50 µg/mL), mientras que los extractos de B. trimera y B. punctulata mostraron este efecto a 5 y 10 µg/mL. Además, por presentar mayor inducción de la proliferación, se realizó un fraccionamiento con diferentes solventes del extracto metanólico de B. notosergila y B. punctulata. La fracción de acetato de etilo de ambos extractos vegetales aumentó la proliferación celular, sugiriendo que compuestos de polaridad media son los responsables de esta actividad. Estos resultados demuestran que los extractos de B. trimera, B. notosergila y B. punctulata poseen actividad inmunomoduladora sobre células mononucleares humanas y servirán de base a otros estudios para determinar el o los componentes activos de los extractos sobre el sistema inmune(AU)

Plants used in traditional medicine are an important source of compounds with immunomodulatory activity. Species of the genus Baccharis, popularly known as "Jaguareteka'a" in our country, are used in folk medicine for the treatment of liver, gastrointestinal, inflammatory and infectious diseases. In this study, we evaluated the immunomodulatory activity of methanolic extracts of three species of the genus Baccharis (B. trimera, B. notosergila and B. punctulata) on the proliferation of human peripheral blood mononuclear cells. Extracts of the three species studied stimulated the proliferation of mononuclear cells. The extract of B. notosergila stimulated cell proliferation at all concentrations tested, while extracts of B. trimera and B. punctulata stimulated at 5 and 10 µg/mL. In addition, we carried out a separation with different solvents of the methanolic extract of B. notosergila and B. punctulata. The ethyl acetate fraction of both plant extracts induced the proliferation of immune cells. These results show that the extracts of B. trimera, B. notosergila and B. punctulata had immunomodulatory activity on human mononuclear cells. Future work will be required to identify the components responsible for the activity on the immune system(AU)

Rational evolution of the unusual Y-type oxyanion hole of Rhodococcus sp. CR53 lipase LipR.

Rhodococcus sp CR-53 lipase LipR was the first characterized member of bacterial lipase family X. Interestingly, LipR displays some similarity with α/ß-hydrolases of the C. antartica lipase A (CAL-A)-like superfamily (abH38), bearing a Y-type oxyanion hole, never found before among bacterial lipases. In order to explore this unusual Y-type oxyanion hole, and to improve LipR performance, two modification strategies based on site directed or saturation mutagenesis were addressed. Initially, a small library of mutants was designed to convert LipR Y-type oxyanion hole (YDS) into one closer to those most frequently found in bacteria (GGG(X)). However, activity was completely lost in all mutants obtained, indicating that the Y-type oxyanion hole of LipR is required for activity. A second approach was addressed to modify the two main oxyanion hole residues Tyr110 and Asp111, previously described for CAL-A as the most relevant amino acids involved in stabilization of the enzyme-substrate complex. A saturation mutagenesis library was prepared for each residue (Tyr110 and Asp111), and activity of the resulting variants was assayed on different chain length substrates. No functional LipR variants could be obtained when Tyr110 was replaced by any other amino acids, indicating that this is a crucial residue for catalysis. However, among the Asp111 variants obtained, LipR D111G produced a functional enzyme. Interestingly, this LipR-YGS variant showed less activity than wild type LipR on short- or mid- chain substrates but displayed a 5.6-fold increased activity on long chain length substrates. Analysis of the 3D model and in silico docking studies of this enzyme variant suggest that substitution of Asp by Gly produces a wider entrance tunnel that would allow for a better and tight accommodation of larger substrates, thus justifying the experimental results obtained.

Presente y futuro de los anticuerpos recombinantes terapéuticos / Present and future of therapeutic recombinant antibodies

Los anticuerpos constituyen un componente fundamental del sistema inmune, permitiendo el reconocimiento con alta especificidad y posterior destrucción de moléculas extrañas. Los anticuerpos monoclonales, producidos por la tecnología del hibridoma, presentan desventajas para su uso en terapia humana debido a su origen en una especie diferente. La ingeniería genética posibilitó la utilización de los anticuerpos monoclonales para terapias humanas, generando los anticuerpos recombinantes terapéuticos. Así, los anticuerpos recombinantes se han transformado en un importante grupo de fármacos; con decenas de ellos aprobados para terapia humana y cientos en desarrollo. Se utilizan con éxito como tratamiento para un amplio rango de patologías, tales como cáncer, autoinmunidad e infecciones, siendo desde hace años el biofármaco con mayores ventas. Inicialmente todos los anticuerpos recombinantes terapéuticos presentaban la estructura convencional de los anticuerpos. Sin embargo, más recientemente, se han generado nuevos diseños que no poseen las características estructurales naturales, como los anticuerpos de simple cadena y bi-específicos. Debido al desarrollo y éxito de la tecnología de anticuerpos recombinantes, se espera un aumento constante en el número de anticuerpos terapéuticos contra nuevos blancos, además de la generación de nuevas estructuras, usos y estrategias terapéuticas. En esta revisión, nos centraremos en las características estructurales y los nuevos formatos de anticuerpos, así como su aplicación clínica en el tratamiento de diversas patologías. Además analizaremos los nuevos formatos de anticuerpos que se encuentran en el mercado y la aparición de los anticuerpos biosimilares.

Antibodies are a key component of the immune system, acting in the highly specific recognition and subsequent destruction of foreign molecules. Monoclonal antibodies produced by hybridoma technology have disadvantages for use in human therapy becauseof its origin in a different species. Genetic engineering enabled the use of monoclonalantibodies for human therapies, generating recombinant therapeutic antibodies. Thus, the recombinant antibodies have become an important group of drugs; dozens of them are approved for human therapy and there are hundreds in development. They are successfully used as a treatment for a wide range of pathologies, such as cancer, autoimmunity and infections, being the biopharmaceutical with higher sales. Initially therapeutic recombinant antibodies showed the conventional structure of the antibodies. However, more recently, new designs that do not have natural structural features havebeen generated such as single chain formats and bi-specific antibodies. Due to development and success of recombinant antibody technology, a steady increase in the number of newtherapeutic drugs against new targets is expected in addition to the generation of new structures, uses and therapeutic strategies. In this review, we will focus on their structural features and clinical application in the treatment of various pathologies. We will also discuss new formats of antibodies and the emergence of biosimilar antibodies.

Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients.

Gastric cancer (GC) is the third most common cause of cancer death worldwide. Natural killer cells play an important role in the immune defense against transformed cells. They express the activating receptor NKG2D, whose ligands belong to the MIC and ULBP/RAET family. Although it is well established that these ligands are generally expressed in tumors, the association between their expression in the tumor and gastric mucosa and clinical parameters and prognosis of GC remains to be addressed. In the present study, MICA and MICB expression was analyzed, by flow cytometry, in 23 and 20 pairs of gastric tumor and adjacent non-neoplasic gastric mucosa, respectively. Additionally, ligands expression in 13 tumors and 7 gastric mucosa samples from GC patients were evaluated by immunohistochemistry. The mRNA levels of MICA in 9 pairs of tumor and mucosa were determined by quantitative PCR. Data were associated with the clinicopathological characteristics and the patient outcome. MICA expression was observed in 57% of tumors (13/23) and 44% of mucosal samples (10/23), while MICB was detected in 50% of tumors (10/20) and 45% of mucosal tissues (9/20). At the protein level, ligand expression was significantly higher in the tumor than in the gastric mucosa. MICA mRNA levels were also increased in the tumor as compared to the mucosa. However, clinicopathological analysis indicated that, in patients with tumors >5 cm, the expression of MICA and MICB in the tumor did not differ from that of the mucosa, and tumors >5 cm showed significantly higher MICA and MICB expression than tumors ≤5 cm. Patients presenting tumors >5 cm that expressed MICA and MICB had substantially shorter survival than those with large tumors that did not express these ligands. Our results suggest that locally sustained expression of MICA and MICB in the tumor may contribute to the malignant progression of GC and that expression of these ligands predicts an unfavorable prognosis in GC patients presenting large tumors.

Sorting nexin 17 regulates ApoER2 recycling and reelin signaling.

ApoER2 is a member of the low density-lipoprotein receptor (LDL-R) family. As a receptor for reelin, ApoER2 participates in neuronal migration during development as well as synaptic plasticity and survival in the adult brain. A previous yeast two-hybrid screen showed that ApoER2 is a binding partner of sorting nexin 17 (SNX17) - a cytosolic adaptor protein that regulates the trafficking of several membrane proteins in the endosomal pathway, including LRP1, P-selectin and integrins. However, no further studies have been performed to investigate the role of SNX17 in ApoER2 trafficking and function. In this study, we present evidence based on GST pull-down and inmunoprecipitation assays that the cytoplasmic NPxY endocytosis motif of ApoER2 interacts with the FERM domain of SNX17. SNX17 stimulates ApoER2 recycling in different cell lines including neurons without affecting its endocytic rate and also facilitates the transport of ApoER2 from the early endosomes to the recycling endosomes. The reduction of SNX17 was associated with accumulation of an ApoER2 carboxy-terminal fragment (CTF). In addition, in SNX17 knockdown cells, constitutive ApoER2 degradation was not modified, whereas reelin-induced ApoER2 degradation was increased, implying that SNX17 is a regulator of the receptor's half-life. Finally, in SNX17 silenced hippocampal and cortical neurons, we underscored a positive role of this endosomal protein in the development of the dendritic tree and reelin signaling. Overall, these results establish the role of SNX17 in ApoER2 trafficking and function and aid in identifying new links between endocytic trafficking and receptor signaling.

A sorting nexin 17-binding domain within the LRP1 cytoplasmic tail mediates receptor recycling through the basolateral sorting endosome.

Sorting nexin 17 (SNX17) is an adaptor protein present in early endosomal antigen 1 (EEA1)-positive sorting endosomes that promotes the efficient recycling of low-density lipoprotein receptor-related protein 1 (LRP1) to the plasma membrane through recognition of the first NPxY motif in the cytoplasmic tail of this receptor. The interaction of LRP1 with SNX17 also regulates the basolateral recycling of the receptor from the basolateral sorting endosome (BSE). In contrast, megalin, which is apically distributed in polarized epithelial cells and localizes poorly to EEA1-positive sorting endosomes, does not interact with SNX17, despite containing three NPxY motifs, indicating that this motif is not sufficient for receptor recognition by SNX17. Here, we identified a cluster of 32 amino acids within the cytoplasmic domain of LRP1 that is both necessary and sufficient for SNX17 binding. To delineate the function of this SNX17-binding domain, we generated chimeric proteins in which the SNX17-binding domain was inserted into the cytoplasmic tail of megalin. This insertion mediated the binding of megalin to SNX17 and modified the cell surface expression and recycling of megalin in non-polarized cells. However, the polarized localization of chimeric megalin was not modified in polarized Madin-Darby canine kidney cells. These results provide evidence regarding the molecular and cellular mechanisms underlying the specificity of SNX17-binding receptors and the restricted function of SNX17 in the BSE.

An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.

Phage display library technology is a common method to produce human antibodies. In this technique, the immunoglobulin variable regions are displayed in a bacteriophage in a way that each filamentous virus displays the product of a single antibody gene on its surface. From the collection of different phages, it is possible to isolate the virus that recognizes specific targets. The most common form in which to display antibody variable regions in the phage is the single chain variable fragment format (scFv), which requires assembly of the heavy and light immunoglobulin variable regions in a single gene. In this work, we describe a simple and efficient method for the assembly of immunoglobulin heavy and light chain variable regions in a scFv format. This procedure involves a two-step reaction: (1) DNA amplification to produce the single strand form of the heavy or light chain gene required for the fusion; and (2) mixture of both single strand products followed by an assembly reaction to construct a complete scFv gene. Using this method, we produced 6-fold more scFv encoding DNA than the commonly used splicing by overlap extension PCR (SOE-PCR) approach. The scFv gene produced by this method also proved to be efficient in generating a diverse scFv phage display library. From this scFv library, we obtained phages that bound several non-related antigens, including recombinant proteins and rotavirus particles.

Analysis of rotavirus non-structural protein NSP5 by mass spectrometry reveals a complex phosphorylation pattern.

Genomic replication and partial assembly of Rotavirus takes place in cytoplasmic viral structures called viroplasms. NSP5 is a viral phosphoprotein localized in viroplasms and its expression is imperative for viral cycle progress. During infection three isoforms of NSP5 can be observed by SDS-PAGE (26, 28 and 33-35kDa) and previous reports suggested that they differ in their phosphorylation patterns. In this study we obtained NSP5 from infected cells and by mass spectrometry we were able to identify nine phosphorylation sites. We detected that in all the isoforms the same residues can be found either phosphorylated or unmodified. Quantitative analysis showed that the 28kDa isoform has a higher phosphorylation level than the 26kDa isoform suggesting that migration properties depend on the total number of phosphorylated residues. Moreover, we identified two not previously described modifications for this protein: an N-acetylation in Serine-2 and an intramolecular disulfide bond in a highly conserved motif, CXXC which is located between two charged alpha-helix motifs.

Avaliação da adesividade de seis cimentos obturadores dos canais radiculares através do teste de cisalhamento / Evaluation of the adhesiveness of six root canal obturator cements by the shear test

O presente estudo tem como finalidade avaliar a resistência de união de seis cimentos obturadores de canais radiculares, cimento Acroseal, Endorez, Endofill, Intrafill e Sealer 26. Para tal, foram utilizados 30 corpos de prova, compostos por 30 dentes humanos, molares superiores e inferiores, onde os mesmos foram incluídos em um tubo de PVC, de ½ polegada, com altura de 5 cm, preenchido com resina acrílica, com finalidade de fixar o dente e preencher espaços entre o dente e o tubo de PVC. Os corpos de prova tiveram a oclusal seccionadas através da máquina Extec Labcut 1010, obtendo uma superfície plana em dentina que foi preparada com uma lixa n° 600 e EDTA 17%, superfície esta que foi utilizada para a colocação do cimento endodôntico e cimentação de um quadrado de guta percha tendo diâmetro de 7X7mm de área de superfície, com altura de 1,5mm. Em seguida os corpos de provas foram divididos em 6 grupos de 5 espécimes, a saber: G 1: 5 dentes, dentina, Acroseal e guta percha; G2: 5 dentes, dentina, CPM e guta percha; G3: 5 dentes, dentina, Endofill e guta percha; G4: 5 dentes, dentina, Endorez e guta percha; G5: 5 dentes, dentina, Intrafill e guta percha; G6: 5 dentes, dentina, Sealer 26 e guta percha. Os corpos de provas foram submetidos ao teste mecânico de cisalhamento, na máquina Emic DL500MF, com célula de carga de 500N e velocidade de 0,5mm/min. Após a leitura dos resultados, foi realizado à análise através do método estatístico Student-Newman-Keuls e, dessa forma, podemos concluir que o cimento endodôntico Sealer 26, foi o que apresentou o melhor resultado.

The purpose of the present study was to evaluate the bond strength of six root canal obturator cements, Acroseal, Endorez, Endofill, Intrafill and Sealer 26. For this purpose, 30 specimens were used, composed of 30 human teeth, upper molars and lower parts, where they were included in a ½ inch PVC pipe, 5 cm high, filled with acrylic resin, to fix the tooth and fill gaps between the tooth and the PVC tube. The specimens were occlusal sectioned through the Extec Labcut 1010 machine, obtaining a flat dentin surface that was prepared with No. 600 sandpaper and 17% EDTA, which was used for the placement of endodontic cement and cementation of a dentin. gutta percha square having a surface area diameter of 7X7mm, with a height of 1.5mm. Then the specimens were divided into 6 groups of 5 specimens, namely: G1: 5 teeth, dentin, Acroseal and gutta percha; G2: 5 teeth, dentin, CPM and gutta percha; G3: 5 teeth, dentin, endofill and gutta percha; G4: 5 teeth, dentin, endorez and gutta percha; G5: 5 teeth, dentin, Intrafill and gutta percha; G6: 5 teeth, dentin, Sealer 26 and gutta percha. The specimens were submitted to the mechanical shear test on the Emic DL500MF machine, with 500N load cell and 0.5mm / min speed. After reading the results, we performed the analysis using the Student-Newman-Keuls statistical method and, therefore, we can conclude that the Sealer 26 endodontic cement presented the best result.